Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs Esomeprazole High-Dose Dual Therapy for H. pylori Eradication
NCT06811207Phase 3Enrolling by invitation
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Feb 2025
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Proportion of Participants With Eradication of H. pylori Confirmed by Urea Breath Test (UBT). Started Feb 2025; status: enrolling by invitation.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06811207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811207.